Table 1. Summary of molecular aberrations in genes, receptors, and pathways by various CLIA-certified methods for osteosarcoma Patient #1 and their targeted agents.
| Detection Method/Therapy | Oncogenic pathway for potential targeted therapy | Chemosensitivity markers | ||||
|---|---|---|---|---|---|---|
| P13K/AKT/mTOR | RAS | c-MET | PTPRD/STAT3 | SPARC | TLE3 | |
| FoundationOne | V334G | amplification | mutation | |||
| Caris Life Sciences | WT - V334 G not tested | no by FISH | ||||
| MD Anderson Cancer Center | V334G | |||||
| Morphoproteomics, University of Texas Houston | p-mTOR,p-AKT | ERK | expression | |||
| Targeted therapy | mTOR therapy or P13K | MEK inhibitor | Crizotinib | STAT 3 inhibitor/IGF1R inhibitor | Abraxane | Taxane |